Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects With Selected Relapsed/Refractory B Cell Malignancies

NCT06014762 is registered in ClinicalTrials.gov with Poseida Therapeutics, Inc. as lead sponsor.

NCT NCT06014762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06014762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects With Selected Relapsed/Refractory B Cell Malignancies
Lead sponsor
Poseida Therapeutics, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 16, 2024
Completion date
March 31, 2041
Enrollment
120 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, not otherwise specified, dlbcl, dlbcl - diffuse large b cell lymphoma, dlbcl arising from follicular lymphoma, dlbcl nos, dlbcl, diffused large b cell lymphoma, follicular lymphoma grade 3b, high-grade b-cell lymphoma, primary mediastinal large b-cell lymphoma (pmbcl), transformed follicular lymphoma (tfl)